278-279 / 2001
•
Intermediate-risk patients
should be considered on
an
individual case basis
.
I
di
i k i
i h
•
nterme ate-r s pat ents w t
favorable features may
appropriately be treated with
PPB monotherapy but results
from confirmatory clinical trials
are pending.